Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI – Research Report), Envista Holdings (NVST – Research Report) and Arrowhead Pharmaceuticals (ARWR – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cigna (CI)
In a report released yesterday, Jason Cassorla from Guggenheim maintained a Buy rating on Cigna, with a price target of $334.00. The company’s shares closed last Thursday at $284.53.
According to TipRanks.com, Cassorla is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Cigna is a Strong Buy with an average price target of $329.38, which is a 18.8% upside from current levels. In a report issued on January 22, RBC Capital also maintained a Buy rating on the stock with a $344.00 price target.
See the top stocks recommended by analysts >>
Envista Holdings (NVST)
In a report released today, Allen Lutz from Bank of America Securities reiterated a Buy rating on Envista Holdings, with a price target of $32.00. The company’s shares closed last Thursday at $24.71.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Envista Holdings with a $26.67 average price target, representing a 12.2% upside. In a report released today, Leerink Partners also upgraded the stock to Buy with a $35.00 price target.
Arrowhead Pharmaceuticals (ARWR)
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $80.00. The company’s shares closed last Thursday at $64.64.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $82.00 average price target, which is a 22.4% upside from current levels. In a report issued on January 22, B. Riley Securities also maintained a Buy rating on the stock with a $101.00 price target.
